Neurocrine Biosciences (NASDAQ:NBIX) Director Sells $44,700.00 in Stock

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Director George Morrow sold 300 shares of the business’s stock in a transaction on Friday, October 30th. The shares were sold at an average price of $149.00, for a total transaction of $44,700.00. Following the transaction, the director owned 10,386 shares in the company, valued at approximately $1,547,514. This represents a 2.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Neurocrine Biosciences Stock Up 13.4%

Shares of Neurocrine Biosciences stock traded up $19.50 on Tuesday, hitting $164.85. 4,056,875 shares of the company traded hands, compared to its average volume of 1,234,742. Neurocrine Biosciences, Inc. has a 12-month low of $122.14 and a 12-month high of $186.12. The company has a market cap of $16.76 billion, a PE ratio of 24.17, a PEG ratio of 0.64 and a beta of 0.36. The company has a 50-day moving average price of $146.49 and a 200 day moving average price of $147.45.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings data on Monday, November 2nd. The company reported $3.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.91 by $1.38. The business had revenue of $1.12 billion during the quarter, compared to analyst estimates of $1.04 billion. Neurocrine Biosciences had a return on equity of 22.43% and a net margin of 20.91%. Neurocrine Biosciences’s quarterly revenue was up 41.3% compared to the same quarter last year. During the same period last year, the company earned $2.04 earnings per share. Equities research analysts anticipate that Neurocrine Biosciences, Inc. will post 7.72 EPS for the current year.

Institutional Investors Weigh In On Neurocrine Biosciences

Large investors have recently bought and sold shares of the business. Basecamp Wealth Advisors LLC increased its position in Neurocrine Biosciences by 582.9% during the first quarter. Basecamp Wealth Advisors LLC now owns 239 shares of the company’s stock worth $31,000 after buying an additional 204 shares during the last quarter. Raleigh Capital Management Inc. raised its holdings in Neurocrine Biosciences by 561.8% during the third quarter. Raleigh Capital Management Inc. now owns 225 shares of the company’s stock valued at $32,000 after buying an additional 191 shares in the last quarter. Cassaday & Co Wealth Management LLC bought a new position in Neurocrine Biosciences during the first quarter valued at about $33,000. Ascentis Independent Advisors acquired a new stake in shares of Neurocrine Biosciences in the first quarter worth about $40,000. Finally, TrinityBridge Ltd acquired a new stake in shares of Neurocrine Biosciences in the second quarter worth about $45,000. 92.59% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts have weighed in on NBIX shares. Mizuho raised Neurocrine Biosciences to a “hold” rating in a research report on Wednesday, September 16th. BMO Capital Markets reduced their price target on Neurocrine Biosciences from $164.00 to $150.00 and set a “market perform” rating for the company in a report on Monday, October 12th. Stifel Nicolaus boosted their price target on Neurocrine Biosciences from $188.00 to $215.00 and gave the company a “buy” rating in a research note on Friday, July 31st. TD Cowen increased their price objective on Neurocrine Biosciences from $200.00 to $220.00 and gave the stock a “buy” rating in a report on Friday, July 31st. Finally, Citigroup increased their price objective on Neurocrine Biosciences from $249.00 to $253.00 and gave the stock a “buy” rating in a report on Thursday, September 3rd. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $201.55.

Trending Headlines about Neurocrine Biosciences

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: Quarterly results topped expectations. Revenue increased 41% year over year to $1.12 billion, and earnings were $3.29 per share. Product sales exceeded $1 billion for the first time, with strong demand across the portfolio. Neurocrine Biosciences Reports Third-Quarter 2026 Financial Results
• Positive Sentiment: INGREZZA guidance was raised. Neurocrine now expects 2026 net sales of $2.9 billion to $2.925 billion, reflecting continued demand for its leading product. The company also cited growth from Crenessity. NBIX Beats on Q3 Earnings & Sales, Raises ’26 Ingrezza Sales View
• Positive Sentiment: Several analysts lifted price targets. Canaccord raised its target to $220 and kept a Buy rating; Piper Sandler raised its target to $215 with an Overweight rating, and RBC raised its target to $190 with an Outperform rating. Canaccord Genuity Group recommendations
• Neutral Sentiment: Neurocrine announced a Phase 2 Alzheimer’s study and plans to present its scientific and neuropsychiatry pipeline at the NEI Fall Congress. These developments may support longer-term pipeline visibility, but no study results were reported. Neurocrine Starts Phase 2 Alzheimer’s Study
• Neutral Sentiment: Morgan Stanley raised its price target to $185 but maintained an Equal Weight rating, signaling a more cautious view than the other target increases. Morgan Stanley recommendations

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc is a San Diego-based biopharmaceutical company focused on discovering, developing and commercializing medicines for neurological, neuroendocrine and psychiatric disorders. The company’s research programs target conditions in which treatments may address significant unmet medical needs.

Neurocrine’s leading product is INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor approved in the United States for the treatment of tardive dyskinesia and chorea associated with Huntington’s disease.